Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL808696 | 0.91 | MMP8 (0.46) | LMNAGAAEPHX2MEN1KMT2A | |
| SCHEMBL4332587 | 0.91 | MMP8 (0.46) | LMNAGAAEPHX2MEN1KMT2A | |
| SCHEMBL2787810 | 0.90 | LMNA (0.40) | LMNAGAAEPHX2MEN1KMT2A | |
| SCHEMBL808641 | 0.89 | LMNA (0.41) | LMNAGAAEPHX2TACR1MEN1 | |
| SCHEMBL808708 | 0.89 | CASR (0.48) | LMNAGAAEPHX2MMP8CASR | |
| SCHEMBL808801 | 0.88 | LMNA (0.44) | LMNAGAAEPHX2TACR1MEN1 | |
| SCHEMBL809208 | 0.88 | LMNA (0.40) | LMNAGAAEPHX2TACR1MEN1 | |
| SCHEMBL808637 | 0.87 | POLB (0.47) | LMNAGAADRD4ALDH1A1HTT | |
| SCHEMBL808680 | 0.85 | SSTR4 (0.41) | LMNAGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL808767 | 0.84 | OPRD1 (0.39) | LMNAGAAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1593674-B1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7683215-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-23 | — | — | US | disclosed |
| US-7671213-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20080076941-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ITAGAKI MAKOTO | 2008-03-27 | — | — | US | disclosed |
| US-20080076931-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ITAGAKI MAKOTO | 2008-03-27 | — | — | US | disclosed |
| US-7288674-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-10-30 | — | — | US | disclosed |
| US-20060149077-A1 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1593674-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149077-A1 | Optically active bisoxazoline compounds, process for production of the same and use thereof | ACSL3, ADSL, SQLE | LMNA 2541/4885GAA 2693/4885EPHX2 369/4885 |
| US-20080076941-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ACSL3, ADSL, SQLE | LMNA 2541/4885GAA 2693/4885EPHX2 369/4885 |
| US-20080076931-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ACSL3, ADSL, SQLE | LMNA 2541/4885GAA 2693/4885EPHX2 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.